Biomarker-driven therapies for triple-negative breast cancer | Dr Giuseppe Curigliano at ECC 2015 - 101271

Spotlight
Video

Biomarker-driven therapies for triple-negative breast cancer | Dr Giuseppe Curigliano at ECC 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular subgroups of triple-negative breast cancer that may have potential to be exploited for clinical trial development of new therapies, including enzalutamide, an androgen receptor signalling inhibitor; and pembrolizumab, an anti-PD-1 monoclonal antibody.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 11/17/15
Added : 2 years ago
Category : Breast Cancer



Recommended

Nothing found.

More From EMJ

Nothing found.